A5101782518- Ocular Oncology and Treatments
- Immunotherapy and Immune Responses
- Nanoplatforms for cancer theranostics
- T-cell and B-cell Immunology
Inserm
2024
Institut Curie
2023-2024
Immunité et Cancer
2024
Uveal melanoma (UM) is the most common cancer of eye. The loss chromosome 3 (M3) associated with a high risk metastases. M3 tumors are more infiltrated by T-lymphocytes than low-risk disomic-3 (D3) tumors, contrasting other tumor types in which T cell infiltration correlates better prognosis. Whether these cells represent an antitumor response and how would be primed eye both unknown. Herein, we characterized infiltrating primary UMs. CD8+ Treg were abundant D3 tumors. CD39+PD-1+CD8+...
Uveal melanoma (UM), an uncommon but aggressive eye cancer, exhibits genetic diversity, classifying into M3 (poor prognosis) and D3 (better outcome) subsets. Despite low mutation rates, metastatic UM patients have detectable CD4 CD8 T cells, suggesting immune response. We recently identified public neo-antigens generated by SF3B1 mutations in tumors, triggering CD8+ cell responses. In tumors with BAP1 inactivation, infiltration increases, specificity remains unclear. collected blood tumor...